Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.

Kashiwagi S, Yoshida S, Yamaguchi H, Mitsui N, Tanigawa M, Shiosakai K, Yamanouchi N, Shiozawa T, Yamaguchi F.

J Infect Chemother. 2013 Apr;19(2):223-32. doi: 10.1007/s10156-012-0481-9. Epub 2012 Oct 20.

PMID:
23085742
2.

Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.

Ikematsu H, Kawai N.

Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7. doi: 10.1586/eri.11.112. Review.

PMID:
21973296
3.

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.

Sugaya N, Ohashi Y.

Antimicrob Agents Chemother. 2010 Jun;54(6):2575-82. doi: 10.1128/AAC.01755-09. Epub 2010 Apr 5.

4.

The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season.

Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.

J Infect Chemother. 2014 Feb;20(2):81-5. doi: 10.1016/j.jiac.2013.07.013. Epub 2013 Dec 11.

PMID:
24486167
5.

Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance.

Kashiwagi S, Yoshida S, Yamaguchi H, Niwa S, Mitsui N, Tanigawa M, Shiosakai K, Yamanouchi N, Shiozawa T, Yamaguchi F.

Int J Antimicrob Agents. 2012 Nov;40(5):381-8. doi: 10.1016/j.ijantimicag.2012.06.017. Epub 2012 Aug 4. Review.

PMID:
22871369
6.

Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.

Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y; MARVEL Study Group.

Clin Infect Dis. 2010 Nov 15;51(10):1167-75. doi: 10.1086/656802. Epub 2010 Oct 11.

7.

Neuraminidase inhibitors for preventing and treating influenza in children.

Wang K, Shun-Shin M, Gill P, Perera R, Harnden A.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD002744. doi: 10.1002/14651858.CD002744.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD002744.

PMID:
22258949
8.

Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.

Kakuta M, Kubo S, Tanaka M, Tobiume S, Tomozawa T, Yamashita M.

Antiviral Res. 2013 Oct;100(1):190-5. doi: 10.1016/j.antiviral.2013.08.004. Epub 2013 Aug 15.

PMID:
23954190
9.

Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.

Yamashita M.

Antivir Chem Chemother. 2010;21(2):71-84. doi: 10.3851/IMP1688. Review.

PMID:
21107016
10.

Effect of a single inhalation of laninamivir octanoate in children with influenza.

Katsumi Y, Otabe O, Matsui F, Kidowaki S, Mibayashi A, Tsuma Y, Ito H.

Pediatrics. 2012 Jun;129(6):e1431-6. doi: 10.1542/peds.2011-2054. Epub 2012 May 21.

11.

A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases.

Watanabe A.

J Infect Chemother. 2013 Feb;19(1):89-97. doi: 10.1007/s10156-012-0460-1. Epub 2012 Aug 21.

PMID:
22907567
12.
13.

Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.

Ishizuka H, Toyama K, Yoshiba S, Okabe H, Furuie H.

Antimicrob Agents Chemother. 2012 Jul;56(7):3873-8. doi: 10.1128/AAC.06456-11. Epub 2012 Apr 23.

14.

Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013-2014 Japanese season.

Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.

J Infect Chemother. 2015 Nov;21(11):802-7. doi: 10.1016/j.jiac.2015.08.013. Epub 2015 Sep 26.

PMID:
26410550
15.

Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.

Nakano T, Okumura A, Tanabe T, Niwa S, Fukushima M, Yonemochi R, Eda H, Tsutsumi H.

Scand J Infect Dis. 2013 Jun;45(6):469-77. doi: 10.3109/00365548.2012.763104. Epub 2013 Feb 4.

PMID:
23373850
16.

Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial.

Kashiwagi S, Watanabe A, Ikematsu H, Awamura S, Okamoto T, Uemori M, Ishida K.

J Infect Chemother. 2013 Aug;19(4):740-9. doi: 10.1007/s10156-013-0622-9. Epub 2013 Jun 4.

17.

Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection.

Mizuno T, Mizuno S, Kanda T.

PLoS One. 2014 Apr 3;9(4):e92601. doi: 10.1371/journal.pone.0092601. eCollection 2014.

18.
19.

Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B.

Kawai N, Ikematsu H, Kawashima T, Maeda T, Ukai H, Hirotsu N, Iwaki N, Kashiwagi S.

Influenza Other Respir Viruses. 2013 May;7(3):448-55. doi: 10.1111/j.1750-2659.2012.00421.x. Epub 2012 Aug 16.

20.

Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season.

Koseki N, Kaiho M, Kikuta H, Oba K, Togashi T, Ariga T, Ishiguro N.

Influenza Other Respir Viruses. 2014 Mar;8(2):151-8. doi: 10.1111/irv.12147. Epub 2013 Aug 19.

Items per page

Supplemental Content

Write to the Help Desk